Safety Reading Notes

Read safety context beside the research guide.

The Opioid receptor cross-talk source set includes safety-context rows around noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 33522084

Mechanistic research summary: mechanistic or pharmacological (1)

PubMed For Dummies Article

Opioid receptor cross-talk Evidence Review: the long-form source walk-through

Quick read
  • Opioid receptor cross-talk currently has 27 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33522084
  • The evidence classes most visible in the row language are insufficient (17), mechanistic or pharmacological (9), and preclinical (1). PMID 31899693
  • The study-design language most visible in the row language is Narrative or expert review (14), Animal study (8), Cellular or in vitro study (3), and other mapped categories (2). PMID 21740450
  • The repeated topics are receptor, target, or pharmacology mechanisms (15), TRPM8 (3), Pain-related outcomes (2), TRPV3 (2), and other mapped categories (5), which tells the reader where to start opening PubMed and DOI links. PMID 23924692

Start with the research question

Opioid receptor cross-talk is built from 27 source-backed evidence row(s) and 25 research source(s). The current evidence classes read as insufficient (17), mechanistic or pharmacological (9), and preclinical (1), and the study-design language most often reads as Narrative or expert review (14), Animal study (8), Cellular or in vitro study (3), and other mapped categories (2). PMID 33522084

The row-level question is not simply whether Opioid receptor cross-talk is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are receptor, target, or pharmacology mechanisms (15), TRPM8 (3), Pain-related outcomes (2), TRPV3 (2), and other mapped categories (5). PMID 21557733

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 39657242

Preclinical evidence 1 row

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 42212209

Mechanistic evidence 9 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 40432283

Limits and uncertainty 18 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 36439263

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 21557733

Where this page has the most source density

The largest bucket surfaced for this page is receptor, target, or pharmacology mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is receptor, target, or pharmacology mechanisms, which gives readers another way to see what the literature repeatedly circles. PMID 33522084

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 21557733

Bucket chapters: what the literature is circling

receptor, target, or pharmacology mechanisms

6 research sources 6 rows (253-261) Mechanistic and preclinical research summary: insufficient (3), mechanistic or pharmacological (2), preclinical (1)

Opioid receptor cross-talk appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 6 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 33522084

Read this bucket as closer to a real-world question, then check the study population, dose, product, comparator, and endpoint before generalizing beyond the source. PMID 33522084

  • Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

  • Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

receptor, target, or pharmacology mechanisms

5 research sources 5 rows (259-267) Mechanistic research summary: insufficient (3), mechanistic or pharmacological (2)

Opioid receptor cross-talk appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 5 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 21557733

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 21557733

  • Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

  • Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome m... PMID 11347816

receptor, target, or pharmacology mechanisms

4 research sources 4 rows (258-265) Mechanistic research summary: insufficient (2), mechanistic or pharmacological (2)

Opioid receptor cross-talk appears in rows about receptor, target, or pharmacology mechanisms mechanisms. It currently draws from 4 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 36439263

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 36439263

  • Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

  • Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: re... PMID 28861502

TRPM8

2 research sources 2 rows (1055-1060) Mapped evidence with interpretation limits: insufficient (2)

Opioid receptor cross-talk appears in rows about TRPM8 mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 29470146

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 29470146

  • Evidence row 1055

    Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, o... PMID 29470146

  • Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

TRPV3

2 research sources 2 rows (1011-1014) Mapped evidence with interpretation limits: insufficient (2)

Opioid receptor cross-talk appears in rows about TRPV3 mechanisms. It currently draws from 2 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 20942817

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 20942817

  • Evidence row 1011

    Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, d... PMID 20942817

  • Evidence row 1014

    Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPV3 channel activity, binding, signaling, dermatolog... PMID 26845556

Appetite and metabolic outcomes

1 research source 78 Mapped evidence with interpretation limits: insufficient (1)

Opioid receptor cross-talk appears in rows studying Appetite and metabolic outcomes. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 21740450

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 21740450

  • Evidence row 78

    THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 21740450

GPR18

1 research source 958 Mapped evidence with interpretation limits: insufficient (1)

Opioid receptor cross-talk appears in rows about GPR18 mechanisms. It currently draws from 1 research source(s), and mechanistic evidence should stay separate from human-outcome evidence. PMID 29138268

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 29138268

  • Evidence row 958

    Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29138268

noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms

1 research source 1147 Mechanistic research summary: mechanistic or pharmacological (1)

Opioid receptor cross-talk appears in rows studying noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 17698254

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 17698254

  • Evidence row 1147

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study d... PMID 17698254

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (9 row(s)), and safety/tolerability context (1 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33522084

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 21557733

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 18755158
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 22585736
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 16107637

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33522084

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 21557733

Source-reading checklist for Opioid receptor cross-talk

  1. Open the linked PubMed or DOI record. PMID 35091505
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 15589342
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 28861502
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 33631255
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 11347816

Source Notes

Opioid receptor cross-talk source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 69

    CBG studied for Pain-related outcomes; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: pain-related outcomes). PMID 31899693

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases.
  2. Evidence row 78

    THCV studied for Appetite and metabolic outcomes; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: appetite-related or metabolic outcomes). PMID 21740450

    Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
  3. Evidence row 253

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33522084

    Evidence class: insufficient; Study design: Animal study. Source: Differential contribution of CB1, CB2, 5-HT1A, and PPAR-γ receptors to cannabidiol effects on ischemia-induced emotional and cognitive impairments.
  4. Evidence row 254

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 23924692

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
  5. Evidence row 255

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 39657242

    Evidence class: insufficient; Study design: Narrative or expert review. Source: A novel insight into the antidepressant effect of cannabidiol: possible involvement of the 5-HT1A, CB1, GPR55, and PPARγ receptors.
  6. Evidence row 256

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 42212209

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabidiol: Pharmaceutical formulations and biomedical applications.
  7. Evidence row 257

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 40432283

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol dose dependently reduces alcohol intake in mice via a non-5-HT1A receptor mechanism: Exploration of other potential receptor targets.
  8. Evidence row 258

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Systematic review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 36439263

    Evidence class: insufficient; Study design: Systematic review. Source: Cys-loop receptors on cannabinoids: All high?
  9. Evidence row 259

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 21557733

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Allosteric modulation of glycine receptors.
  10. Evidence row 260

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 18755158

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine.
  11. Evidence row 261

    CBD modulates receptor, target, or pharmacology mechanisms; evidence class: preclinical (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 22585736

    Evidence class: preclinical; Study design: Animal study. Source: Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors.
  12. Evidence row 262

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 16107637

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids.
  13. Evidence row 263

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 35091505

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Mu Opioid Receptors Acutely Regulate Adenosine Signaling in Striatal Glutamate Afferents.
  14. Evidence row 264

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 15589342

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse.
  15. Evidence row 265

    Endocannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 28861502

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoids in Parkinson's Disease.
  16. Evidence row 266

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: receptor, target, or pharmacology mechanisms). PMID 33631255

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Tolerance to alcohol: A critical yet understudied factor in alcohol addiction.
  17. Evidence row 267

    Cannabinoids modulates receptor, target, or pharmacology mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: receptor, target, or pharmacology mechanisms). PMID 11347816

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Activation of nicotinic receptors on GABAergic amacrine cells in the rabbit retina indirectly stimulates dopamine release.
  18. Evidence row 696

    CBC studied for Pain-related outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: pain-related outcomes). PMID 41322279

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.
  19. Evidence row 739

    THCV studied for safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: safety, tolerability, adverse-event, impairment, THC-interaction, or formulation-specific concerns). PMID 21740450

    Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₁-independent mechanisms of Δ⁹-THCV, AM251 and SR141716 (rimonabant).
  20. Evidence row 958

    Endocannabinoids modulates GPR18; evidence class: insufficient (study design: Narrative or expert review; outcome measure: GPR18 receptor activity, binding, signaling, or pharmacology). PMID 29138268

    Evidence class: insufficient; Study design: Narrative or expert review. Source: N-Acyl Amino Acids (Elmiric Acids): Endogenous Signaling Molecules with Therapeutic Potential.
  21. Evidence row 1011

    Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 20942817

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Pharmacogenetics of new analgesics.
  22. Evidence row 1014

    Cannabinoids modulates TRPV3; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: TRPV3 channel activity, binding, signaling, dermatology-relevant mechanism, or pharmacology). PMID 26845556

    Evidence class: insufficient; Study design: Systematic review. Source: A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders.
  23. Evidence row 1024

    Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  24. Evidence row 1055

    Cannabinoids modulates TRPM8; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  25. Evidence row 1059

    Endocannabinoids modulates TRPM8; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 39684707

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: TRPM8's Role in the Shift Between Opioid and Cannabinoid Pathways in Electroacupuncture for Inflammatory Pain in Mice.
  26. Evidence row 1060

    Cannabinoids modulates TRPM8; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPM8 channel activity, binding, signaling, or pharmacology). PMID 21622235

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Effects of opioids, cannabinoids, and vanilloids on body temperature.
  27. Evidence row 1147

    Noladin ether studied for noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: noladin ether biology, receptor pharmacology, metabolism, physiology, or safety-relevant mechanisms). PMID 17698254

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.